For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has
been characterized by critical progress that has contributed to substantially improved …

Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …

Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …

Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in
resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials. gov …

Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

PURPOSE The open-label, phase III POSEIDON study evaluated tremelimumab plus
durvalumab and chemotherapy (T+ D+ CT) and durvalumab plus chemotherapy (D+ CT) …

Immunotherapies such as immune checkpoint blockade (ICB) and adoptive cell therapy
(ACT) have revolutionized cancer treatment, especially in patients whose disease was …

First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …